Quantitative multiparameter assays to measure the effect of adjuvants on human antigen-specific CD8 T-cell responses.
Large numbers and functionally competent T cells are required to protect from diseases for which antibody-based vaccines have consistently failed (1), which is the case for many chronic viral infections and solid tumors. Therefore, therapeutic vaccines aim at the induction of strong antigen-specific T-cell responses. Novel adjuvants have considerably improved the capacity of synthetic vaccines to activate T cells, but more research is necessary to identify optimal compositions of potent vaccine formulations. Consequently, there is a great need to develop accurate methods for the efficient identification of antigen-specific T cells and the assessment of their functional characteristics directly ex vivo. In this regard, hundreds of clinical vaccination trials have been implemented during the last 15 years, and monitoring techniques become more and more standardized.
Derré
Laurent
L
Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland.
Jandus
Camilla
C
Baumgaertner
Petra
P
Posevitz
Vilmos
V
Devêvre
Estelle
E
Romero
Pedro
P
Speiser
Daniel E
DE
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000276:immunology*; D049109:Cell Proliferation; D002478:Cells, Cultured; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects*
D000276:Adjuvants, Immunologic